Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2025-03-12 Report Publication Anno…
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Master Investor Conference Attendance
Report Publication Announcement Classification · 1% confidence The document is identified by the RNS Number header and the presence of 'RNS Number' and 'National Storage Mechanism'. The content announces that the company leadership will be presenting at the 'Master Investor Show in London'. This is an announcement about a future event where the company will communicate with investors, which aligns best with an Investor Presentation (IP) or a general announcement. Since it is an announcement about participation in an investor event rather than the presentation material itself, and it is distributed via RNS, it fits the criteria for a general regulatory announcement. However, given the context of presenting the 'Ananda Pharma opportunity' to investors, it is a form of investor communication. If the presentation slides were attached, it would be IP. Since it is just the announcement of attendance and presentation time, it is best classified as a general Regulatory Filing (RNS) or potentially related to Investor Presentation (IP). Given the options, and that it is a formal RNS release announcing participation in an investor event, RNS is the most appropriate general category for this type of market update that isn't a core financial report or specific corporate action. It is not a DEF 14A (Remuneration), DIRS (Director Dealing), or DIV (Dividend). It is a market communication, making RNS the safest fit as a general regulatory announcement.
2025-03-12 English
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is an official announcement disseminated via RNS (Regulatory Information Service) and concerns a transaction by a Director/PDMR (Persons Discharging Managerial Responsibilities). Specifically, it details the purchase of 20,000,000 ordinary shares by the Chief Executive Officer, Melissa Sturgess. This type of insider transaction reporting falls directly under the definition of Director's Dealing (DIRS). Although it is distributed via RNS, the specific content dictates the DIRS classification over the general RNS fallback.
2025-03-04 English
CEO Presenting at Private Investor Conference
Investor Presentation Classification · 1% confidence The document is an official announcement disseminated via RNS (RNS Number : 9219X) on February 21, 2025. The content explicitly states that the CEO will be 'presenting to the Talman House private members' event in Zurich' and that the company is 'pleased to announce' this event. This describes an upcoming investor presentation or participation in an investor conference, which aligns best with the Investor Presentation (IP) category, as it is an announcement about the company's engagement with investors, rather than the presentation material itself. Since it is a formal announcement distributed through the regulatory news service (RNS), and it details an investor-facing event, IP is the most specific fit. It is not a general regulatory filing (RNS) because a more specific category (IP) applies. It is not an AGM-R because it is not about the AGM itself.
2025-02-21 English
Achievement of Manufacturing Milestone for MRX1
Legal Proceedings Report Classification · 1% confidence The document is identified by the presence of 'RNS Number' and the closing statement referencing 'RNS, the news service of the London Stock Exchange' and 'Market Abuse Regulation (MAR) Disclosure'. This indicates it is a regulatory news service announcement. The content describes a specific operational achievement ('Achievement of Manufacturing Milestone for MRX1') and provides updates on clinical trial preparation, rather than being a full financial report (like 10-K or IR) or a proxy statement. Since it is a general, time-sensitive regulatory announcement that doesn't fit perfectly into the other specific categories (like DIV, DIRS, or ER), the most appropriate classification is the general regulatory filing category.
2025-02-20 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains structured data fields typical of regulatory filings concerning changes in share ownership thresholds. Specifically, it details the 'Resulting situation' of voting rights (9.12%) after an acquisition/disposal, referencing directives like DTR5.1 and DTR5.2.1. This type of filing, which reports changes in significant shareholdings (crossing thresholds), corresponds directly to the Major Shareholding Notification category (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2025-02-18 English
Investor Webinar
Report Publication Announcement Classification · 1% confidence The document is identified by the RNS Number header and contains a formal announcement dated February 7, 2025. The content announces that the CEO will be presenting at an 'Investor Webinar' on a future date (February 25, 2025) and provides links for registration and contact information. This is a general announcement to investors regarding a future event, not a core financial report (like 10-K, IR, ER) or a specific transaction report (like DIRS, DIV, POS). Since it is a formal regulatory announcement distributed via RNS that doesn't fit a more specific category (like AGM-R, CT, or IP), it falls best under the general Regulatory Filings category (RNS) or potentially a related event announcement, but RNS is the most appropriate catch-all for formal regulatory news releases that aren't financial statements or specific corporate actions listed elsewhere.
2025-02-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.